Source: Getty Images BCG shortages and the fragile BCG supply chain created a bladder cancer treatment vacuum. For more than 40 years, intravesical bacillus Calmette-Guérin (BCG) has been the mainstay ...
Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback